Molecular Partners AG ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
8.3%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$7Mnext fiscal year
FY EPS (est.)
-$1.47next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Interim Management Statement Q3 2026 (unaudited) | 29 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Short-Term Deposits Quarterly79MTarget: Sufficient to fund operations into late 2027
Active Clinical Sites for MP0712 Phase 1/2a Trial Quarterly4.0Target: 9 active sites by end of 2026
Watch Items
- Initial clinical data readout for lead Radio-DARPin candidate MP0712Trigger: Presentation of Phase 1/2a safety, imaging, and dosimetry dataAction: Evaluate therapeutic index, tumor uptake, and biodistribution to confirm competitive profile of the Lead-212 platform
- First-in-human imaging initiation for MP0726 (targeting MSLN)Trigger: IND clearance and first patient dosed with MP0726Action: Assess target engagement and select optimal isotope payload (e.g., Lead-212 or Actinium-225)
Research as of 20 Jun 2026